Therapeutic efficacy of J-111,225, a novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenem, against experimental murine systemic infections.

Abstract

In a murine model of systemic infection with methicillin-resistant Staphylococcus aureus (MRSA), J-111,225 showed an ED(50) value of 5. 83 mg/kg, which was comparable to vancomycin (ED(50) 4.84 mg/kg), whereas imipenem failed to cure infected mice (ED(50) >100 mg/kg). Against a mixed infection caused by MRSA and Pseudomonas aeruginosa, monotherapy with J-111,225 showed an ED(50) value of 7.23 mg/kg, whereas combined treatment with vancomycin plus imipenem (1:1) had an ED(50) of 20.86 mg/kg. J-111,225 showed good therapeutic efficacy against methicillin-susceptible S. aureus, penicillin-resistant Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae and P. aeruginosa. The unusually broad spectrum suggests that monotherapy with this novel carbapenem may be suitable for polymicrobial infections associated with MRSA.

• Authors: K Shibata, R Nagano, T Hashizume, H Morishima
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 45 Issue 3 Pg. 379-82 (Mar 2000) ISSN: 0305-7453 [Print] England
• PMID: 10702562 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• J 111225

Topics

• Animals
• Anti-Bacterial Agents (pharmacokinetics, pharmacology, therapeutic use)
• Bacteria (drug effects)
• Bacterial Infections (drug therapy, metabolism, microbiology)
• Carbapenems (pharmacokinetics, pharmacology, therapeutic use)
• Methicillin Resistance
• Mice
• Mice, Inbred ICR
• Microbial Sensitivity Tests
• Pseudomonas Infections (drug therapy, microbiology)